Search results :

Docetaxel

More information: STITCH, PubChem (stereo-specific compounds: 1, 2) and possibly Wikipedia

ATC Code: L01CD02

Side effects

Options: Show MedDRA Preferred Terms,   display all 26 labels

Side effect Data for drug Placebo Labels
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Agranulocytosis 10% - 87% x
Neutropenia very common, 1% - 95.5% x x x x x x x x x x x x x x x x x x x x
Gastrointestinal disorder 45% x x x x x x x
Lymphopenia 40% - 98% x
Amenorrhoea 27.2% - 59.9% x x x x x x x x x x x x x x
Alopecia very rare, 0% - 98% x x x x x x x x x x x x x x x x x x x x
Mucosal inflammation 40% x x x x x x x x x x x x
Nervous system disorder 32% x x x x x x x
Connective tissue disorder 27% x x x x x
Menstruation irregular 19.9% - 33.6% x x x x
Phosphatase alkaline increased 1% - 51% x x x
Lethargy 1% - 62.9% x x x x x x x x x x x x x
Stomatitis 0% - 68% x x x x x x x x x x x x x x x x x x x
Nausea 1% - 87.2% x x x x x x x x x x
Anaemia 1% - 96.8% x x x x x x x x x x x x x x x x x x x
Diarrhoea 0.9% - 77.8% x x x x x x x x x x x x x x x x x x x
Vomiting postmarketing, 1% - 73.2% x x x x x x x x x x
Dysphagia 0.6% - 26% x x x x x x x x x x x x
Odynophagia 0.6% - 26% x x x x x x x x x x x x
Mental disorder 12% x x x x x
Cancer pain 0.6% - 21% x x x x x x x x x x x
Febrile neutropenia 2% - 26% x x x x x x x x x x x x x x x x x x x
Eye disorder postmarketing, 21% x x x x x x x
Mediastinal disorder postmarketing, 20% x x x x x x x
Anorexia postmarketing, 0% - 54% x x x x x x x x x x x x x x x x x x
Oesophagitis postmarketing — 0.6% - 26% x x x x x x x x x x x x x x x x x x
Asthenia 1% - 43% x x x x x x x x x x x x x x x x x x x
Paraesthesia 1% - 15% x x x x x x x x
Neutropenic infection 1.19% - 15.9% x x x x x x x x x x x x
Haemoglobin decreased 4% - 13% x x x x
Arthralgia 0% - 39.7% x x x x x x x x x x x x x x x x x x x
Edema of lower extremities 1% - 14% x x x x x
Infection postmarketing, 0% - 37% x x x x x x x x x x x x x x x x x x x
Injection site reaction 6% x x x x x
Blood bilirubin increased 2% - 23% x x x x x x x
Fatigue 2.7% - 81.3% x x x x x x x x x x x x x x x x x
Cramp muscle 1% - 15% x x x x x x x x x
Neuropathy peripheral 1% - 10% x x x x x x x
Thrombocytopenia rare, 0% - 47% x x x x x x x x x x x x x x x x x x x
Gastrointestinal pain 1% - 15% x x x x x x x x x x x x
Parosmia 0% - 20% x x x x x x x x x x x
Dermatitis 1% - 9% x x x x x x x x
Throat sore 1% - 11% x x x x x
Headache 1% - 8% x x x x x x x x
Extravasation 3.3% - 5.6% x x x x x x x x x x x x x x x x x x x
Inflammation 3.3% - 5.6% x x x x x x x x x x x x x x x x x x x
Swelling 3.3% - 5.6% x x x x x x x x x x x x x x x x x x x
Redness 3.3% - 5.6% x x x x x x x x x x x x x x x x x x
Pain in extremity 1% - 8% x x x x x x x x
Dizziness 0% - 16% x x x x x x x x x x x x x
Body temperature increased 0% - 37% x x x x x x x x x x x x x x x x x x x
Heartburn 0% - 13% x x x x x x x x
Weight decreased 0% - 27% x x x x x x x x x x x x
Aspartate aminotransferase increased 0.5% - 42% x x x x x x x x x x x x x x x x x x
Decreased appetite 4% - 10% x x x x x x x x
Rash erythematous 4% x x x x x x x x
Infusion site reactions 3% - 5.6% x x x x x x x x x x x x x x x x x
Skin hyperpigmentation postmarketing, 3.3% - 5.6% x x x x x x x x x x x x x x x x x x x
Back pain 1% - 7% x x x x x x x x x x x x x x x x x x x
Abdominal pain upper 1% - 6% x x x x x x x x
Oral candidiasis 1% - 7% x x x x x x x x
Myalgia 0% - 50.9% x x x x x x x x x x x x x x x x x x x
Dyspepsia 1% - 5% x x x x x x x x
Nail discolouration 1% - 4% x x x x x x x x
Arrhythmia postmarketing — 0% - 6% x x x x x x x x x x x x x x x x x x x
Hyperbilirubinaemia 2% - 6% x x x x x
Leukopenia 2% - 3% x x x x x x x x x x x x x x x x
Blood alkaline phosphatase increased 0.3% - 4%
Hypertension postmarketing — 1.6% - 2% x x x x x x x x x x x x x x x x x x x
Alanine aminotransferase increased 2% - 1.3% x x x x
Constipation postmarketing — 0% - 38% x x x x x x x x x x x x x x x x x x
Oedema 0% - 27% x x x x x x x x x x x x x x
Rash 0% - 25.9% x x x x x x x x x x x x x x x x x x x
Gastrointestinal haemorrhage postmarketing — 0% - 5% x x x x x x x x x x x x x x x x
Pharyngitis 0% - 65% x x x x x x x x x x x x x x x x
Myocardial ischaemia 0% - 2.7% x x x x x x x x x x x x
Skin exfoliation 0% - 25.9% x x x x x x x x x x x x x x x x
Fluid retention postmarketing, 0% - 52.2% x x x x x x x x x x x x x x x x x x x
Dyspnoea postmarketing — 0.3% - 9% x x x x x x x x x x x x x x x x x x x
Onycholysis postmarketing, 1% - 5% x x x x x x x x x x x x x x x x x x
Skin toxicity 0% - 1% x x x x x x x x x x x x x x x x
Cardiac failure 0% - 2.17% x x x x x x x x x x x x x x x x x x x
Neuropathy 0% - 44.8% x x x x x x x x x x x x x x x x x
Abdominal pain postmarketing — 0% - 9% x x x x x x x x x x x x x x x x x x
Anaphylactic shock postmarketing, rare x x x x x x x x x x x x x
Atrial fibrillation postmarketing, rare x x x x x x x x x x x x x x
Chest pain postmarketing — common x x x x x x x x x x x x x x x x x x
Colitis very rare, postmarketing x x x x x x x x x x x x x x x x x x
Confusional state postmarketing, rare x x x x x x x x x x x x x x
Conjunctivitis postmarketing — 0% - 1.1% x x x x x x x x x x x x x x x x x x x
Dehydration postmarketing — 1% - 8% x x x x x x x x x x x x x x x x x x
Scleroderma very rare, postmarketing x x x x x x x x x
Disseminated intravascular coagulation postmarketing x x x x x x x x x x x x x
Duodenal ulcer very rare, postmarketing x x x x x x x x x x x x x x
Enterocolitis postmarketing x x
Toxic epidermal necrolysis very rare, postmarketing x x x x x x x x x x x x x x
Erythema multiforme very rare, postmarketing x x x x x x x x x x x x x x x x
Cardiac failure congestive postmarketing, uncommon x x x x x x x x
Haemorrhage postmarketing, rare x x x x x x x x x x x x x x x x x x x x
Hepatitis very rare, postmarketing x x x x x x x x x x x x x x x x x x
Hypersensitivity postmarketing, 0% - 10.4% x x x x x x x x x x x x x x x x x x x
Hyponatraemia postmarketing x x x x x x
Intestinal obstruction very rare, postmarketing x x x x x x x x x x x x x x x x x x
Lacrimal duct obstruction postmarketing, rare x x x x x x x x x x x x x x x x x
Acute myeloid leukaemia very rare, postmarketing x x x x x x x x x x x x x x x
Liver disorder very rare, postmarketing x x x x x x x x x
Cutaneous lupus erythematosus postmarketing x x x x x x x x
Lymphatic disorder postmarketing x x x x
Cystoid macular oedema postmarketing x x x x x
Multi-organ failure postmarketing x x x x x x x x x x x x x
Myelodysplastic syndrome very rare, postmarketing x x x x x x x x
Myocardial infarction very rare, postmarketing x x x x x x x x x x x x x x x x x x
Neoplasm postmarketing x x x
Pain postmarketing — 0% - 2% x x x x x x x x x x x x x x x x x x x
Pneumonia postmarketing, 22% x x x x x x x x x x x
Pulmonary oedema postmarketing, rare x x x x x x x x x x x x x x x x x x
Pulmonary embolism very rare, postmarketing x x x x x x x x x x x x x x
Pulmonary fibrosis postmarketing, rare x x x x x x x x x x x x x x x x x
Renal failure postmarketing, rare x x x x x x x x x x x x x
Acute respiratory distress syndrome postmarketing, rare x x x x x x x x x x x x x x x x x x
Scotoma postmarketing x x x x x x x x x x x x x x x x
Convulsion postmarketing, rare x x x x x x x x x x x x x x x x x x
Stevens-Johnson syndrome very rare, postmarketing x x x x x x x x x x x x x x x x x x
Syncope postmarketing — 0% - 1% x x x x x x x x x x x x x x x x x x
Tachycardia postmarketing — 1% - 1.4% x x x x x x x x x x x x x x x x
Thrombophlebitis very rare, postmarketing x x x x x x x x x x x x x x x x
Loss of consciousness postmarketing, rare x x x x x x x x x x x x x x x x x x
Erythema postmarketing x x x x x x x x
Photopsia postmarketing x x x x x x x x x x x x x x x x
Deep vein thrombosis very rare, postmarketing x x x x x x x x x x x x x x
Gastrointestinal perforation very rare, postmarketing x x x x x x x x x x x x x x x x x x
Lacrimation increased postmarketing — 5% - 12% x x x x x x x x x x x x x x x x x x x
Acute pulmonary oedema postmarketing, rare x x x x x x x x x x x x x x
Malnutrition postmarketing, 22% x x x x x x x x x
Colitis ischaemic very rare, postmarketing x x x x x x x x x x x x x x x x x x
Interstitial pneumonia postmarketing, rare x x x x x x x x x x x x x x x x x x
Interstitial lung disease postmarketing x x x x x x x
Radiation pneumonitis postmarketing x x x x x x x x x x x x x
Fatal outcomes very rare, postmarketing x x x x x x x x x x
Bullous eruption very rare, postmarketing x x x x x x x x x x x x x x x x x x
Sepsis postmarketing x x x x x x x x x x x x x x
Neutropenic enterocolitis very rare, postmarketing x x x x x x x x x x x x x x x x
Lupus erythematosus very rare, postmarketing x x x x x
Lacrimation postmarketing — 0% - 9.3% x x x x x x x x x x x x x x
Pain localised postmarketing, common x x x x x
Visual disturbance postmarketing x x x x x x x x x x x x x x x x
Ear and labyrinth disorders postmarketing x x x x x x x
Hand and foot syndrome secondary to sickle cell anaemia postmarketing x x x x x x x x x x
Respiratory failure postmarketing x x x x x x x
Ileus very rare, postmarketing x x x x x x x x x x x x x x x x x x
Recall phenomenon very rare, postmarketing x x x x x x x x x x x x x x
Renal impairment postmarketing, rare x x x x x x x x x x x x x x x x x x
Angina unstable x x x x x x x x x x
Ascites x x x x x x x
Ataxia x
Atrial flutter x x x x x x x x x x
Bone disorder x x x x x
Breast disorder x x x
Bronchospasm x x x x x
Bronchopneumonia x
Congestive cardiomyopathy
Cough 0% - 9% x x x x x x x x x x x x x x x x
Cyst x x x
Dysgeusia postmarketing — 0% - 29.5% x x x x x x x x x x x x x x x x x x
Effusion x x
Enteritis x x x x x x x x x x x
Epistaxis 0% - 5% x x x x x x x x x x x x x x x x
Flushing 0% x x x x x x x x x x x x x x x x x x x
Cardiac disorder x x x x x x x
Haemorrhoids x
Coma hepatic x
Hypoaesthesia x x x x x x
Hypotension postmarketing — 0% x x x x x x x x x x x x x x x x x x x
Orthostatic hypotension x
Immune system disorder x x x
Jaundice x
Lacrimal disorder 0% x x x x x x x x x x x
Lymphoedema postmarketing, 0% - 54.5% x x x x x x x x x x x x x x x
Nail disorder postmarketing, 0% - 50% x x x x x x x x x x x x x x x x x x
Nasopharyngitis x x x x x
Necrosis x
Neuralgia x
Oliguria x x x x
Otitis media x
Palpitations 0% x x x x
Pericardial effusion x x x x x
Phlebitis 0% - 8% x x x x x x x x x x x x x x x x x x x
Pleural effusion x x x x x x x x x x x x x
Polyp x x x
Prurigo x x x
Pruritus x x x x x x x x x x x x x x x x x x x
Rhinitis 0% x x x x
Skin disorder x x
Sinus tachycardia 0% x x x x x x x x x x x x x x
Supraventricular tachycardia x
Urinary tract disorder x x x
Angiopathy x x x x x x x
Weight increased 0% - 6% x x x x x x x x x x x x x x x x x x
Dry mouth 0% - 4% x x x x x x x x
Chills 0% x x x x x x x x x x x x x x x x x x x
Hepatic failure x
Burning sensation x
Oedema peripheral 0% x
Acute leukaemia x x x
Lower respiratory tract infection x
Migraine x
Diarrhoea haemorrhagic x
Large intestine perforation x x x x x x x x x x x
Liver function test abnormal x x x x x x x x x x x
Bone pain x x x x x x x
Dry skin 0% - 6% x x x x x x x x x x x
Oesophageal ulcer x
Polyneuropathy x
Unspecified disorder of skin and subcutaneous tissue x x x x x x
Lightheadedness x x x x
Injection site infection x
Chest tightness x x x x x x x x x x x x x x x x x x x
Nail changes 0% - 46.4% x x x x x x x x x x x x x x x x
Peripheral motor neuropathy x x x
Neurotoxicity x x x x x x x x
Eye irritation x
Ototoxicity x x x x
Hepatotoxicity x x x x x x
Auditory disorder NOS x
Onychomadesis x
Hepatobiliary disease x x x
Eruption x x x x x x x x x x x x x x x
Dysaesthesia x x x x x x x x
Rigors 0% x x x x x
Liver function test normal x x x x x x
Non-cardiac chest pain x x
Blood pressure increased x
Localized rash x x x x x x x x x x x x x x x
Rash generalised x x x x x
Necrotizing enterocolitis x
Influenza like illness x x x x x
Reaction gastrointestinal x x x x x x x x x x x
Prothrombin level decreased x
Cutaneous hypersensitivity x
Hot flush 0% x x x x x x x
Carcinoma breast x x x x x
Carcinoma of lung x x x x x
Drug interaction x
Infestation NOS x x x x
Blood and lymphatic system disorders x x x x
General disorders and administration site conditions x
Myelosuppression x
Thromboembolic event x x x x
Pharyngolaryngeal pain x x x x x
Cardiotoxicity x x
Neutropenic sepsis x x x x
Raised liver function tests x x
Insomnia 0% x x x x x x x x
Infusion site reaction x x x x
Ovarian cancer x
Nail toxicity x x
Rhinorrhoea x x x x x
Death x x x x x
Drug fever x x x x x x x x x x x x x x x
Hearing impaired x x x
Exfoliative rash x x x
Radiation recall reaction (dermatologic) x
Ageusia x
Fluid imbalance x
Somnolence x x x
Metastatic disease x
Tearing eyes x
Advanced breast cancer x x x x x x x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

docetaxel / docetaxel

Side effects:4
Source:EMA

Docetaxel

Side effects:61
Source:BC Cancer

docetaxel / Taxotere

Side effects:88
Source:FDA

docetaxel / Taxotere

Side effects:90
Source:FDA

docetaxel / Taxotere

Side effects:99
Source:FDA

docetaxel / Taxotere

Side effects:106
Source:FDA

DOCETAXEL ANHYDROUS

Side effects:118
Source:FDA Structured Product Label

docetaxel / Taxotere

Side effects:124
Source:FDA

docetaxel anhydrous

Side effects:137
Source:FDA Structured Product Label

DOCETAXEL ANHYDROUS

Side effects:138
Source:FDA Structured Product Label

DOCETAXEL ANHYDROUS

Side effects:142
Source:FDA Structured Product Label

DOCETAXEL ANHYDROUS

Side effects:144
Source:FDA Structured Product Label

docetaxel / docetaxel

Side effects:171
Source:EMA

docetaxel / docetaxel

Side effects:171
Source:EMA

docetaxel / docetaxel, anhydrous

Side effects:174
Source:EMA

Docetaxel / Taxotere, Concentrate for infusion

Side effects:175
Source:Medsafe

DOCETAXEL / TAXOTERE

Side effects:177
Source:Health Canada

AUSTRALIAN APPROVED NAME / TAXOTERE

Side effects:185
Source:medicines.org.au

Color scheme:

standardalternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label